home All News open_in_new Full Article

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T

VANCOUVER, British Columbia — AbCellera (Nasdaq: ABCL) today announced an upcoming poster presentation that includes preclinical in vivo data on its PSMA x CD3 T-cell engagers at the American Association for Cancer ResearchⓇ (AACR) 116th Annual Meeting, to be held April 25 to 30 at the McCormick Place Convention Center in Chicago, Illinois. Details on […]



AbCellera (ABCL) will present preclinical in vivo data on its PSMA x CD3 T-cell engagers at the AACR 2025 meeting in Chicago, April 25-30. The poster presentation, titled "PSMA x CD3 T-cell engagers show preclinical efficacy for the treatment of prostate cancer" (Abstract Number 6012), will be on April 29. AbCellera's T-cell engager platform aims to improve cancer treatment by guiding the immune system to eliminate cancer cells. The phone numbers (604)724-1242, (604)559-9005 and (778)729-9116 are also listed.

today 16 h. ago attach_file Other

attach_file Culture
attach_file Politics
attach_file Other
attach_file Culture
attach_file Economics
attach_file Other
attach_file Culture
attach_file Economics
attach_file Other
attach_file Sport
attach_file Culture
attach_file Society
attach_file Culture
attach_file Events
attach_file Culture
attach_file Economics
attach_file Other
attach_file Other
attach_file Other
attach_file Other


ID: 2026108254
Add Watch Country

arrow_drop_down